Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Lymphoma, Follicular 9Lymphoma, Large B-Cell, Diffuse 6Sarcoma, Synovial 5Sarcoma 4Rhabdoid Tumor 3Mesothelioma 3Lymphoma, B-Cell 3Recurrence 2Prostatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Hematologic Neoplasms 2Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Hepatic Impairment 1Desmoplastic Small Round Cell Tumor 1Chondrosarcoma 1Carcinoma, Renal Cell 1

Interventions

tazemetostat 1capmatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hepatic Impairment × tazemetostat × Clear all
NCT04241835 2026-04-16

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Ipsen

Phase 1 Terminated
18 enrolled
Other solid neoplasm

Hepatic Impairment

Data powered by HemOnc (CC BY 4.0) Colophon âš¡